NASDAQ:SAGE
Sage Therapeutics Stock News
$11.90
-0.440 (-3.57%)
At Close: May 10, 2024
A Wake-Up Call for Bargain Hunters
10:32am, Monday, 04'th Apr 2022
For bargain hunters, every stock market cloud has a silver lining. After a rough first quarter, dozens of stocks have descended to what I consider attractive levels.
Strength Seen in Sage Therapeutics, Inc. (SAGE): Can Its 11.8% Jump Turn into More Strength?
09:02am, Monday, 04'th Apr 2022
Sage Therapeutics, Inc. (SAGE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in th
Expert Ratings For Sage Therapeutics
03:43pm, Thursday, 31'st Mar 2022 Benzinga
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
0
5
0
0
Las
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
02:05pm, Thursday, 31'st Mar 2022 Benzinga
Upgrades
Raymond James upgraded the previous rating for Starwood Property Trust Inc (NYSE:STWD) from Outperform to Strong Buy. For the fourth quarter, Starwood Property Trust had an EPS of $1.10, comp
Sage Therapeutics to Present at 2022 Stifel CNS Days
06:30am, Tuesday, 22'nd Mar 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Sage Therapeutics drug benefits cognitive function in phase 2 trial in Parkinson’s
12:36pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Sage Therapeutics (SAGE) said that data from a phase 2 trial showed SAGE-718 was associated with improvements on multiple tests of functioning and learning and memory in patients with…
Sage Therapeutics Inc. (NASDAQ: SAGE) Stock Seems Like A Good Option
01:00pm, Saturday, 12'th Mar 2022 Stocks Register
Sage Therapeutics Inc. (NASDAQ:SAGE) shares, rose in value on Friday, 03/11/22, with the stock price down by -3.36% to the previous day’s close as strong demand from buyers drove the stock to $31.07. Actively observing the price movement in the last trading, the stock closed the session at $32.15, falling within a range of $31.02 … Sage Therapeutics Inc. (NASDAQ: SAGE) Stock Seems Like A Good Option Read More »
Sage Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
02:10pm, Tuesday, 01'st Mar 2022 Seeking AlphaSage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
09:05pm, Monday, 28'th Feb 2022 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 10:30am ET. A live webcast of the fireside chat can be accessed on the Investor page of Sage’s website at investor.sag
Should WisdomTree U.S. SmallCap ETF (EES) Be on Your Investing Radar?
11:20am, Monday, 28'th Feb 2022 Zacks Investment Research
Style Box ETF report for EES
Expert Ratings For Sage Therapeutics
08:12pm, Friday, 25'th Feb 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding
Sage Therapeutics, Inc. (SAGE) Q4 2021 Earnings Call Transcript
04:13am, Friday, 25'th Feb 2022 AlphaStreet
Sage Therapeutics, Inc. (NASDAQ: SAGE) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Helen Rubinstein — Investor Relations Officer Barry Greene — Chief Executive Officer Jim Doherty — Chief Development Officer Kimi Iguchi — Chief Financial […] The post Sage Therapeutics, Inc. (SAGE) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .
Sage Therapeutics'' (SAGE) CEO Barry Greene on Q4 2021 Results - Earnings Call Transcript
07:20pm, Thursday, 24'th Feb 2022 Seeking AlphaThe Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics
05:03pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.
Sage Therapeutics' (SAGE) CEO Barry Greene on Q4 2021 Results - Earnings Call Transcript
02:20pm, Thursday, 24'th Feb 2022
Sage Therapeutics' (SAGE) CEO Barry Greene on Q4 2021 Results - Earnings Call Transcript